요로감염 치료 시장 : 질환별, 약물군별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Urinary Tract Infection Treatment Market size was valued at USD 9,238.21 Million in 2023, expanding at a CAGR of 3.98% from 2024 to 2032.

Treatment for urinary tract infections (UTIs) usually consists of a mix of prescription drugs, dietary adjustments, and preventative measures. To avoid consequences like kidney infections or repeated infections, proper diagnosis and treatment are essential for UTIs.

Urinary Tract Infection Treatment Market- Market Dynamics

The growing prevalence of urinary infections and advanced diagnostic techniques are expected to propel market demand

The need for efficient treatment alternatives is fueled by the rising prevalence of Urinary Tract infections (UTIs), which are especially common in women, the elderly, and patients with chronic conditions is expected to boost the market growth. Being one of the most prevalent bacterial infections, UTIs require dependable and regular treatment alternatives. Higher diagnosis rates are the result of increased knowledge of UTI symptoms and the significance of prompt treatment. Improved diagnostic instruments and public health initiatives support early detection and treatment, which accelerates market expansion.

The accuracy and speed of diagnosing UTIs are enhanced by technological developments in diagnostic techniques, such as molecular diagnostics and fast urine testing. This improves treatment results and fuels the market for medical devices for diagnosis and treatment. Increasing healthcare spending makes it easier to access medical facilities and UTI treatments, especially in developing nations. The market for UTI treatments is growing because of these economic factors. Additionally, the market is positively impacted by government activities and healthcare organizations' support for better UTI management. These initiatives include funding for research and development, public health campaigns, and enhanced healthcare infrastructure.

Urinary Tract Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.98% over the forecast period (2024-2032)

Based on Disease segmentation, the complicated UTIs segment was predicted to show maximum market share in the year 2023, owing to the growing prevalence of urinary disorders.

Based on Drug Class segmentation, the Quinolones segment was the leading Drug Class in 2023, due to high demand for kidney-related disease treatment.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel in 2023, owing to the high demand for treatment of kidney and diabetic disorders.

On the basis of region, North America was the leading revenue generator in 2023, owing to growing healthcare spending by companies.

Urinary Tract Infection Treatment Market- Segmentation Analysis:

The Global Urinary Tract Infection Treatment Market is segmented on the basis of Disease, Drug Class, Distribution Channel, and Region.

The market is divided into two categories based on Disease: complicated UTIs and uncomplicated UTIs. The complicated UTIs segment dominates the market. Advancement in disease treatment and the adoption of new devices are fueling the segment's growth.

The market is divided into five categories based on the Drug Class: quinolones, beta-lactams, macrolides, aminoglycosides, and others. The quinolones segment dominates the market. The growing demand from people seeking medical attention owing to increased knowledge regarding UTIs is contributing to market growth.

The market is divided into three categories based on Distribution channels: retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. Online pharmacies is expected to grow at the fastest CAGR with the rising e-commerce sector which is accelerating the growth of the market.

Urinary Tract Infection Treatment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is dominating the global market. The region has advanced healthcare infrastructure that supports easy access to diagnosis and treatment. North America has the largest market share due to high healthcare expenditure and the robust pharmaceutical industry. Asia Pacific is estimated to expand at the highest rate over the forecast period.

Urinary Tract Infection Treatment Market- Competitive Landscape:

The Urinary Tract Infection (UTI) treatment market is significantly competitive and comprises several key players involved in the development, manufacturing, and distribution of pharmaceuticals and therapies for UTI management. Companies are engaged in research to develop next-generation antibiotics and treatments aimed at multidrug-resistant infections. For example, GSK plc is involved in collaborative efforts to tackle antimicrobial resistance and has several compounds in clinical trials for bacterial infections.

Recent Developments:

In 2022, Spero Therapeutics Inc. offered an NDA to the US Food and Drug Administration (FDA) and got approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI).

In 2022, BDR Pharma, a leading generic pharmaceutical company in India, introduced biapenem to treat patients with intra-abdominal infections, and complex UTIs.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL URINARY TRACT INFECTION TREATMENT MARKET KEY PLAYERS

• AbbVie Inc.
• Pfizer Inc.
• Johnson & Johnson
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Roche Holding AG
• Allergan plc
• BDR Pharma
• Bayer AG
• Bristol-Myers Squibb
• AstraZeneca plc
• Novartis International AG
• Sanofi S.A.
• Eli Lilly and Company
• Spero Therapeutics
• Paratek Pharmaceuticals
• Iterum Therapeutics
• Others

GLOBAL URINARY TRACT INFECTION TREATMENT MARKET, BY DISEASE- MARKET ANALYSIS, 2019-2032

• Complicated UTIs
• Uncomplicated UTIs

GLOBAL URINARY TRACT INFECTION TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019-2032

• Quinolones
• Beta lactams
• Macrolides
• Aminoglycosides
• Others

GLOBAL URINARY TRACT INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

• Retail pharmacies
• Online pharmacies
• Hospital pharmacies

GLOBAL URINARY TRACT INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Urinary Tract Infection Treatment Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Urinary Tract Infection Treatment Market Snippet by Disease
  • 2.1.2. Urinary Tract Infection Treatment Market Snippet by Drug Class
  • 2.1.3. Urinary Tract Infection Treatment Market Snippet by Distribution Channel
  • 2.1.4. Urinary Tract Infection Treatment Market Snippet by Country
  • 2.1.5. Urinary Tract Infection Treatment Market Snippet by Region
• 2.2. Competitive Insights

3. Urinary Tract Infection Treatment Key Market Trends

• 3.1. Urinary Tract Infection Treatment Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Urinary Tract Infection Treatment Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Urinary Tract Infection Treatment Market Opportunities
• 3.4. Urinary Tract Infection Treatment Market Future Trends

4. Urinary Tract Infection Treatment Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Urinary Tract Infection Treatment Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Urinary Tract Infection Treatment Market Landscape

• 6.1. Urinary Tract Infection Treatment Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Urinary Tract Infection Treatment Market - By Disease

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Disease, 2024 & 2032 (%)
  • 7.1.2. Complicated UTIs
  • 7.1.3. Uncomplicated UTIs

8. Urinary Tract Infection Treatment Market - By Drug Class

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
  • 8.1.2. Quinolones
  • 8.1.3. Beta lactams
  • 8.1.4. Macrolides
  • 8.1.5. Aminoglycosides
  • 8.1.6. Others

9. Urinary Tract Infection Treatment Market - By Distribution Channel

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
  • 9.1.2. Retail pharmacies
  • 9.1.3. Online pharmacies
  • 9.1.4. Hospital pharmacies

10. Urinary Tract Infection Treatment Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Urinary Tract Infection Treatment Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Urinary Tract Infection Treatment Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Urinary Tract Infection Treatment Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Urinary Tract Infection Treatment Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Urinary Tract Infection Treatment Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Urinary Tract Infection Treatment Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. AbbVie Inc.
  • 11.2.2. Pfizer Inc.
  • 11.2.3. Johnson & Johnson
  • 11.2.4. GlaxoSmithKline plc
  • 11.2.5. Merck & Co., Inc.
  • 11.2.6. Roche Holding AG
  • 11.2.7. Allergan plc
  • 11.2.8. BDR Pharma
  • 11.2.9. Bayer AG
  • 11.2.10. Bristol-Myers Squibb
  • 11.2.11. AstraZeneca plc
  • 11.2.12. Novartis International AG
  • 11.2.13. Sanofi S.A.
  • 11.2.14. Eli Lilly and Company
  • 11.2.15. Spero Therapeutics
  • 11.2.16. Paratek Pharmaceuticals
  • 11.2.17. Iterum Therapeutics
  • 11.2.18. Others

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us